Development and functional characterization of novel fully human anti‐CD19 chimeric antigen receptors for T‐cell therapy
Zhenyu Dai(Tongji Hospital), Jianfeng Zhou(Tongji Hospital)
Cited by 7
Related Papers
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
|EBioMedicine|2020|41
Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells
|Clinical Cancer Research|2010|15
Corrigendum to “Human MLL‐AF9 Overexpression Induces Aberrant Hematopoietic Expansion in Zebrafish”
|BioMed Research International|2022|0